BioCentury | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

...president of finance and CFO of the Indian pharma’s research services subsidiary, Syngene International Ltd. Carisma Therapeutics Inc....
BioCentury | Sep 17, 2019
Company News

Penn emerges from Novartis alliance a prolific source of cell, gene therapies

...a professor in immunology at Penn’s School of Medicine. Other spinouts include CAR macrophage company Carisma Therapeutics Inc....
...growth factor receptor variant III Karen Tkach Tuzman, Associate Editor Novartis AG University of Pennsylvania Tmunity Therapeutics Inc. Cabaletta Bio Inc. Carisma Therapeutics Inc. CAR...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

...first investment was in a $53 million series A round for cancer cell therapy play Carisma Therapeutics Inc....
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...scientific initiatives and partnerships at NCI's Frederick National Laboratory for Cancer Research. Macrophage immunotherapy company Carisma Therapeutics Inc....
...Inc. (Cambridge, Mass.) hired Glenn Reicin as CFO. He was president of Greyrock Biomedical Advisors. BioCentury Staff Carisma Therapeutics Inc. Dicerna...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

...tumor-associated immune cells, which it believes can serve as biomarkers for patient selection. Bystander effect Carisma Therapeutics Inc....
...testing of exoSTING in 1H20. Companies and Institutions Mentioned Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Carisma Therapeutics Inc....
...necrosis factor α VISTA - V-region immunoglobulin-containing suppressor of T cell activation Allison Johnson, Staff Writer Clevegen (FP-1305) Carisma Therapeutics Inc. Codiak...
BioCentury | Feb 7, 2019
Finance

Pharma ventures earlier

...director of AbbVie Ventures. Recent seed investments in new therapeutic modalities include 2017 rounds for Carisma Therapeutics Inc....
...North Chicago, Ill. Alector Inc. (NASDAQ:ALEC), South San Francisco, Calif. Arrakis Therapeutics Inc., Waltham, Mass. Carisma Therapeutics Inc....
BioCentury | Jun 29, 2018
Finance

Carisma’s attraction

...Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and...
...to degrade, we could target our macrophage to go after it,” he said. Chris Lieu, Staff Writer Carisma Therapeutics Inc. CT-0508 HealthCap immunotherapy macrophage Steven...
BioCentury | Jun 29, 2018
Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

...Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by...
...Capital participated. Carisma CEO Steven Kelly told BioCentury the round should give the company (formerly Carma Therapeutics...
...Biotech's Eran Nadav and IP Group's Althea Stillman joined Carisma's board. Carisma Therapeutics Inc., Philadelphia, Pa. Chris Lieu CT-0508 (CARMA-0508) Carisma Therapeutics Inc....
BioCentury | Jun 27, 2018
Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

...Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by...
...Capital participated. Carisma CEO Steven Kelly told BioCentury the round should give the company (formerly Carma Therapeutics...
...Regina Hodits, TPG Biotech's Eran Nadav and IP Group's Althea Stillman joined Carisma's board. Chris Lieu Solid tumors Carisma Therapeutics Inc. CT-0508...
BioCentury | Jun 16, 2017
Financial News

Carma raises venture funding

...On June 12, Carma Therapeutics Inc. (Philadelphia, Pa.) raised an undisclosed amount in an "initial" round of...
...participated. Carma is developing chimeric antigen receptor macrophages (CARMAs). Carma Therapeutics Inc. , Philadelphia, Pa. Jaime De Leon Carma Therapeutics...
Items per page:
1 - 10 of 13
BioCentury | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

...president of finance and CFO of the Indian pharma’s research services subsidiary, Syngene International Ltd. Carisma Therapeutics Inc....
BioCentury | Sep 17, 2019
Company News

Penn emerges from Novartis alliance a prolific source of cell, gene therapies

...a professor in immunology at Penn’s School of Medicine. Other spinouts include CAR macrophage company Carisma Therapeutics Inc....
...growth factor receptor variant III Karen Tkach Tuzman, Associate Editor Novartis AG University of Pennsylvania Tmunity Therapeutics Inc. Cabaletta Bio Inc. Carisma Therapeutics Inc. CAR...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

...first investment was in a $53 million series A round for cancer cell therapy play Carisma Therapeutics Inc....
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...scientific initiatives and partnerships at NCI's Frederick National Laboratory for Cancer Research. Macrophage immunotherapy company Carisma Therapeutics Inc....
...Inc. (Cambridge, Mass.) hired Glenn Reicin as CFO. He was president of Greyrock Biomedical Advisors. BioCentury Staff Carisma Therapeutics Inc. Dicerna...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

...tumor-associated immune cells, which it believes can serve as biomarkers for patient selection. Bystander effect Carisma Therapeutics Inc....
...testing of exoSTING in 1H20. Companies and Institutions Mentioned Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Carisma Therapeutics Inc....
...necrosis factor α VISTA - V-region immunoglobulin-containing suppressor of T cell activation Allison Johnson, Staff Writer Clevegen (FP-1305) Carisma Therapeutics Inc. Codiak...
BioCentury | Feb 7, 2019
Finance

Pharma ventures earlier

...director of AbbVie Ventures. Recent seed investments in new therapeutic modalities include 2017 rounds for Carisma Therapeutics Inc....
...North Chicago, Ill. Alector Inc. (NASDAQ:ALEC), South San Francisco, Calif. Arrakis Therapeutics Inc., Waltham, Mass. Carisma Therapeutics Inc....
BioCentury | Jun 29, 2018
Finance

Carisma’s attraction

...Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and...
...to degrade, we could target our macrophage to go after it,” he said. Chris Lieu, Staff Writer Carisma Therapeutics Inc. CT-0508 HealthCap immunotherapy macrophage Steven...
BioCentury | Jun 29, 2018
Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

...Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by...
...Capital participated. Carisma CEO Steven Kelly told BioCentury the round should give the company (formerly Carma Therapeutics...
...Biotech's Eran Nadav and IP Group's Althea Stillman joined Carisma's board. Carisma Therapeutics Inc., Philadelphia, Pa. Chris Lieu CT-0508 (CARMA-0508) Carisma Therapeutics Inc....
BioCentury | Jun 27, 2018
Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

...Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by...
...Capital participated. Carisma CEO Steven Kelly told BioCentury the round should give the company (formerly Carma Therapeutics...
...Regina Hodits, TPG Biotech's Eran Nadav and IP Group's Althea Stillman joined Carisma's board. Chris Lieu Solid tumors Carisma Therapeutics Inc. CT-0508...
BioCentury | Jun 16, 2017
Financial News

Carma raises venture funding

...On June 12, Carma Therapeutics Inc. (Philadelphia, Pa.) raised an undisclosed amount in an "initial" round of...
...participated. Carma is developing chimeric antigen receptor macrophages (CARMAs). Carma Therapeutics Inc. , Philadelphia, Pa. Jaime De Leon Carma Therapeutics...
Items per page:
1 - 10 of 13